New antihyperglycaemic agents and cardiovascular disease

Pafili, Kalliopi; Rizzo, Manfredi; Παπάνας, Νικόλαος

doi:10.1097/hco.0000000000000524

Cited by 6 publications

(4 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Importantly, aggressive lifestyle interventions are necessary in clusters 3 and 5 [14]. As one step forward, an appropriate pharmacological therapy might be considered in selected prediabetes subjects [15,16], particularly with the use of agents with proven cardio-renal benefit in T2DM, such as glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors, in order to provide an effective prevention of chronic complications and to assure a long healthy life to such subjects [17][18][19]. The need to protect kidney function appears especially important in cluster 6, while the need to prevent cardiovascular complications appears especially important in clusters 3 and 5 [10] (Fig.…”

Section: Commentarymentioning

confidence: 99%

New Sub-Phenotyping of Subjects at High Risk of Type 2 Diabetes: What Are the Potential Clinical Implications?

et al. 2021

Self Cite

View full text Add to dashboard Cite

Prediabetes is defined as a condition of abnormal glucose metabolism, characterised by plasma glucose above normal range but not as high as required for the diagnosis of diabetes mellitus (DM). It represents a heterogeneous entity of intermediate glucose metabolism, including impaired fasting glucose, impaired glucose tolerance, and borderline glycated haemoglobin. Prediabetes is being increasingly recognised as an important metabolic state not only predisposing to a higher probability of future progression to DM, but also to an increased risk of different micro- and macrovascular complications. The recently proposed sub-phenotyping of individuals at increased risk of type 2 DM, which distinguishes six different clusters, offers the opportunity for the improvement in screening, prevention, and treatment algorithms. Such progress should also enable more efficient and cost-effective strategies aimed at decreasing the disease burden associated with prediabetes.

show abstract

Section: Commentarymentioning

confidence: 99%

New Sub-Phenotyping of Subjects at High Risk of Type 2 Diabetes: What Are the Potential Clinical Implications?

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Further, Lorenzi et al 6 reported that liraglutide was superior to SGLT-2 inhibitors with regard to glycemic control or body weight, and Kalliopi et al state that SGLT-2 inhibitors and GLP-1RA have similar effects on cardiovascular events. 7 Therefore, in the present study, we investigated the efficacy of a GLP-1RA and SGLT-2 inhibitors on cardiac and renal function in type 2 diabetes patients with renal impairment, specifically focusing on cardiac diastolic function using Japanese standard doses. Further, we compared the data with other studies.…”

Section: Introductionmentioning

confidence: 99%

Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment

Hiramatsu

Ito

Okumura

et al. 2020

Diabetes and Vascular Disease Research

View full text Add to dashboard Cite

Introduction: Diabetes mellitus is a progressive disease with cardiovascular complications. We evaluated the impact of a glucagon like peptide-1 (GLP-1) receptor agonist and sodium glucose cotransporter 2 (SGLT-2) inhibitors dapagliflozin and empagliflozin on renal and cardiac function in type 2 diabetes patients with renal impairment. Materials and methods: A total of 156 patients referred with suboptimal glycemic control were assigned to Group G (GLP-1): n = 72 or Group S (SGLT-2 inhibitor)—dapagliflozin ( n = 52) or empagliflozin ( n = 32). Renal function was assessed every 3 months for 36 months. Cardiovascular parameters were evaluated every 12 months for 36 months. Results: Compared with baseline, HbA1c and systolic blood pressure significantly decreased in both groups ( p < 0.05). The estimated glomerular filtration rate decreased, but without significance. Albuminuria decreased significantly in both groups and then subsequently increased after 30 months in Group S. Diastolic cardiac function, assessed by E/e′ or left atrial volume index, decreased only in Group G at 36 months. Conclusions: The GLP-1 receptor agonist and SGLT-2 inhibitors were effective for glycemic and blood pressure control and for maintaining renal function. The GLP-1 receptor agonist improved diastolic function at 36 months.

show abstract

“…On the other hands, some data also supports the antioxidant property of uric acid plays protective role against the cardiovascular diseases. [4][5][6][7] DOI: 10.29309/TPMJ/2020.27. 2.3500 Great disparity in data from international literature has led us to conduct this study in a Pakistani population where the burden of cardiovascular disease is continuously is on rise besides other conventional risk factors.…”

Section: Introductionmentioning

confidence: 99%

Frequency of Hyperuricemia in the patients with Acute Myocardial Infarction.

Memon

Kazi

et al. 2020

TPMJ

View full text Add to dashboard Cite

Objectives: This study aims to scientifically fill the gap and provide the scientific data regarding frequency of hyperuricemia in the patients with acute myocardial Infarction admitted at Liaquat University of Medical & Health Sciences, Hyderabad. Study Design: Prospective descriptive case series. Setting: Department of Cardiology, Liaquat University of Medical & Health Sciences, Hyderabad. Period: From 7th Feb 2016 to 6th August 2018. Material and Methods: Was conducted on either gender having age ≥35 to ≤70 years presented with ST elevation myocardial infarction was included in the study. ECG and laboratory investigations were carried out. Relevant investigation like serum uric acid was sent to laboratory. Final outcome was assessed at the end of 5th day, hyperuricemia was labeled if serum uric acid levels above 6.5 mg/dl. All the information was noted in proforma and analyzed using SPSS version 21.0. Results: There were 95 male and 50 female patients. The mean age was 49.57 ± 8.53 years, with range 35 (35 - 70) years. The age of 49 (33.8%) patients was ≤45 years and age of 96 (66.2%) patients was >45 years. 17.9% patients were obese and 50.3% patients were hypertensive. The hyperuricemia was present in 27 (18.6%) patients. Among patients who were found with hyperuricemia, the mean age was 49.41 ± 8.34 years. The results showed that significant association of hyperuricemia was observed with obesity. No significant association of hyperuricemia was observed with gender, age, and hypertension. Conclusion: Based on the findings of our study, raised serum uric acid levels are associated with adverse cardiovascular outcome. The prevalence of hyperuricemia is high in a population of patients with acute myocardial infarction.

show abstract

New antihyperglycaemic agents and cardiovascular disease

Cited by 6 publications

References 121 publications

New Sub-Phenotyping of Subjects at High Risk of Type 2 Diabetes: What Are the Potential Clinical Implications?

New Sub-Phenotyping of Subjects at High Risk of Type 2 Diabetes: What Are the Potential Clinical Implications?

Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment

Frequency of Hyperuricemia in the patients with Acute Myocardial Infarction.

Contact Info

Product

Resources

About